AI Article Synopsis
- Many chronic lung diseases involve excessive mucus production, leading to the use of mucoactive agents like N-acetylcysteine (NAC) for treatment.
- A review at the National Aspergillosis Centre highlighted six patients who received NAC, with one experiencing an adverse reaction and two showing significant improvement in symptoms.
- The study also includes a review of existing literature to evaluate NAC's effectiveness in managing respiratory issues characterized by bronchial obstruction.
Article Abstract
Many chronic lung diseases are characterized by the hypersecretion of mucus. In these conditions, the administration of mucoactive agents is often indicated as adjuvant therapy. -acetylcysteine (NAC) is a typical example of a mucolytic agent. A retrospective review of patients with pulmonary aspergillosis treated at the National Aspergillosis Centre in Manchester, United Kingdom, with NAC between November 2015 and November 2017 was carried out. Six Caucasians with lung disease received NAC to facilitate clearance of their viscid bronchial mucus secretions. One patient developed immediate bronchospasm on the first dose and could not be treated. Of the remainder, two (33%) derived benefit, with increased expectoration and reduced symptoms. Continued response was sustained over 6⁻7 months, without any apparent toxicity. In addition, a systematic review of the literature is provided to analyze the utility of NAC in the management of respiratory conditions which have unresponsive bronchial obstruction as a feature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308940 | PMC |
| http://dx.doi.org/10.3390/jof4040117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tigecycline combined with bronchoscopic interventions in the treatment of macrolide-unresponsive pneumonia: A case report.
Heliyon
November 2024
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430030, China.
(MP) is a common etiological agent of community-acquired pneumonia. However, there has been an increasing incidence of macrolide-unresponsive pneumonia (MUMPP) in recent years. The treatment of MUMPP requires further investigation.
View Article and Find Full Text PDFCo-Stimulation with TWEAK and TGF-β1 Induces Steroid-Insensitive TSLP and CCL5 Production in BEAS-2B Human Bronchial Epithelial Cells.
Int J Mol Sci
October 2024
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan.
Steroid-resistant asthma is a common cause of refractory asthma. Type 2 inflammation is the main inflammatory response in asthma, and the mechanism underlying the steroid-resistance of type 2 inflammation has not been completely elucidated. Tumor-necrosis-factor-like apoptosis-inducing factor (TWEAK) and transforming growth factor (TGF)-β1 are involved in epithelial-mesenchymal transition (EMT) and the production of thymic stromal lymphopoietin (TSLP) and C-C motif chemokine ligand 5 (CCL5).
View Article and Find Full Text PDFRapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Bacterial Tracheitis: A New Presentation of a Well-Known Disease.
Cureus
July 2024
Pediatric Intensive Care Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, PRT.
Article Synopsis
- - Bacterial tracheitis (BT) is a rare but serious condition that can lead to severe airway obstruction, primarily exhibiting symptoms like stridor, fever, and rapid breathing, with a recent increase in respiratory distress cases.
- - A case study of a five-year-old boy highlights rapid clinical deterioration despite treatment attempts, including corticosteroids and nebulized epinephrine, ultimately requiring intubation due to respiratory failure.
- - The case emphasizes the need for healthcare professionals to recognize classic and evolving symptoms of BT and be prepared for immediate invasive interventions, as effective treatment can lead to significant recovery.
[Expert consensus on the diagnosis and treatment of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease].
Zhonghua Jie He He Hu Xi Za Zhi
July 2024
The prevalence of pulmonary aspergillosis is increasing in patients with chronic obstructive pulmonary disease (COPD) and can manifest in different forms such as invasive pulmonary aspergillosis (IPA), chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA). With the variations of individual conditions such as immune status, these forms of the disease may transform into each other or even overlap. Moreover, the atypical clinical manifestations and the limited use of invasive sampling techniques have posed a challenge to the diagnosis and treatment of invasive pulmonary aspergillosis in patients with COPD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!